Figure 4

Inhibition of HMGB1 by GLY treatment attenuated the MCT-induced increase of RV systolic pressure and RV hypertrophy. (A) MCT-injected rats exhibited increased RVSP when compared with control rats (*p = 0.002). GLY treatment reduced the MCT-induced increase of RVSP (†p = 0.045 when compared to the MCT group treated for 4 weeks; ‡p = 0.002 when compared to the MCT group treated for 6 weeks). GLY treated alone without MCT yielded no significant difference in RVSP when compared with that of control rats (p = 0.307). (B) RV hypertrophy (RV/(LV + S)) increased significantly in the MCT group when compared with the control group (**p <0.001). GLY treatment reduced the MCT-induced increase of RV hypertrophy, although only rats given a 6-week GLY treatment course exhibited a statistically significant difference (††p = 0.418 when compared with the MCT group treated for 4 weeks; ‡‡p = 0.002 when compared with the MCT group treated for 6 weeks). GLY treated alone without MCT yielded no significant difference in RV hypertrophy when compared with that of controls (p =0.656). Data are presented as means ± SEM.